top of page

investor
Information

Phoenix-logo-21-lime.png

Please note that any investment in Evren is subject to strict compliance with Federal and State securities laws.   Our securities are not being offered through this website, no money or other consideration is being solicited, and if sent in response, it will not be accepted. No offer to buy our securities can be made or accepted, and no part of any purchase price can be received, until official offering documents are available and only through an authorized channel. 

If you are interested in learning where and when Evren securities may be offered in compliance with securities laws, please leave your contact information by selecting "Get Investor Information" below.

Support evren technologies
as we
revolutionize 
PTSD Treatment

FDA Breakthrough Device Designation

Empty Classroom

Let's get together!

Contact us to set a meeting and learn more about

our revolutionary bioelectronic solution to treating PTSD.

June 4-5, 2024

2024 Florida Early Stage Venture Conference

Dr. Phillips Center for the Performing Arts

Orlando, FL

 Opportunity

Are you looking to contribute to medical innovation that will make an impact on the lives of PTSD patients?

Evren is looking for persons to help fund the final stages of FDA clinical trials and go-to-market activities for the Phoenix.

We encourage interested parties to contact us for more information on how to support our efforts. Note: nothing on this website should be considered to be an offering of securities.  Please note that any investment in Evren is subject to strict compliance with Federal and State securities laws.

 

Together, we can empower patients to rise above PTSD and improve their lives.

What is VNS?

The vagus is the key component of the parasympathetic branch of the autonomic nervous system, and because the sympathetic and parasympathetic nervous systems act reciprocally -- when one goes up, the other goes down -- the vagus nerve is critical in many therapeutic areas due to its beneficial effect in restoring balance in cases where sympathetic activity is abnormally raised or parasympathetic activity is lowered.   

 

Researchers are investigating:  VNS mechanisms of action, restoration of autonomic balance, laying new neural pathways during tasks, reduction of symptoms and systemic inflammatory responses and much more.

Weaver Gaines CEO.jpg
Weaver gaines
Ceo/ chairman
Watch the 
Localvest Quick Pitch
presented by
Evren Technologies
on November 2, 2023.

Localvest
Quick Pitch

Weaver Gaines, Evren CEO/ Chairman, answers four questions:

  1. Is PTSD a big enough problem with a serious unmet need?

  2. Does Evren Tech have a solution?

  3. Is the market for a PTSD treatment large enough to be attractive to investors?

  4. Certain statements that we make may constitute “forward-looking statements."

 

Forward-looking statements include information concerning business prospects, financial results (including expenses, earnings, liquidity, cash flow and capital expenditures), industry or market conditions, demand for and pricing of our products, acquisitions and divestitures, and regulatory developments. In addition, words such as “believes,” “expects,” “anticipates,” “intends,” “plans,” “estimates,” “projects,” “forecasts,” and future or conditional verbs such as “will,” “may,” “could,” “should,” and “would,” as well as any other statement that necessarily depends on future events, are intended to identify forward-looking statements. Forward-looking statements are not guarantees, and they involve risks, uncertainties, and assumptions. Although we believe our statements are reasonable, there can be no assurance that actual results will not differ materially from those expressed in the forward-looking statements. We expressly disclaim any obligation to update any forward-looking statement in the event it later turns out to be inaccurate, whether as a result of new information, future events, or otherwise.

Why is this an interesting potential opportunity?

Our disruptive bioelectronic therapeutic technology, along with a multi-billion-dollar market opportunity and unmet medical need, is prime for investment opportunities.

The unmet medical need, clinical validation, patient appeal and product market fit create a favorable position in the rapidly growing bioelectronic, AI and wearable industry segments.

Our demonstrated capacity to raise extramural funds from the NIH and Defense Department, coupled with our potential to capitalize and capture additional funding, make us an attractive investment.

The potential to capture and organize health care clinical outcomes and usage data represents both short- and long-term data collation and treatment algorithm opportunities.

 

Our experienced management, strong IP position and label expansion opportunities resonates with investors.

Contact Us if You Want to be Informed Where and When You May Invest

Thank you for your interest!

Global Data Report

Vagus Nerve Stimulators (VNS) Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies

- SEC Filings-

Form C

 Why does Ptsd matter?

PTSD is a devastating psychiatric disorder caused by exposure to a horrific or life-threatening trauma.  People with PTSD have difficulty sleeping, nightmares, persistent frightening flashbacks, sudden pathologically-intense outbursts of anger, violence, or anxiety, feel numb or detached, and avoid “triggers” (people or places that remind them of the trauma).

The clinical, social, and financial burdens are enormous.  The annual cost to society is estimated at over $232 billion. In the VA alone more than 900,000 veterans receive PTSD disability compensation.

What are the Unmet medical Needs?

There is no cure, and current treatment options are inadequate. Over 12 million Americans have PTSD; 4.2 million of them (35%) never seek help and of the remainder who do seek treatment, few are satisfied with the result.  Among those treated, approximately 2/3 (66%) retained their PTSD diagnosis after treatment.  Only 9% feel fully recovered. Thus, there is an unmet need affecting about 9 4 million Americans with PTSD.

Phoenix-logo-21-lime.png

Phoenix CR
taVNS Research Device

The Phoenix® CR is designed specifically to produce high-quality transcutaneous auricular vagus nerve stimulation (taVNS) data from human clinical trials  

Caution: Investigational Device. Limited by Federal (or United States) Law to Investigational Use.

taVNS Research Areas

  • Traumatic Brain Injury

  • PTSD

  • Anxiety

  • Depression

  • Sleep Disruption

  • Adjustment Disorders

  • Fear

  • Cognition and Learning

  • Tinnitus

Phoenix CR Device

  • Programmable

    • Time

    • Intensity

    • Sham

  • Track usage & adherence

  • Long battery life

Phoenix CR Device
Earpiece

Soft, Conforming Earpiece

  • Made of soft silicone

  • Available in 3 sizes: Small, Medium and Large

“It’s not a drug that I’m putting in my system and its not something that I’m smoking.  So, if you’re telling me that you can put something in my ear and make me better, sign me up every day of the week!”  

 

- Andy, from Evren's PTSD Pilot Study 

bottom of page